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Abbreviations 
SFK: Src family tyrosine kinase 
SH: Src homology 
pY: phosphotyrosine 
Csk: C-terminal Src kinase 
Cbp: Csk binding protein 
PAG: Phosphoprotein associated with GEMs 
Dok: Downstream of tyrosine kinase 
PH: preckstrin homology 
PTB: Phosphotyrosine binding 
IRS: Insulin receptor substrate 
ZO: zona occludins 
PDZ: PSD-95/Dlg/ZO-1 
NLS: nuclear localization signal 
Guk: guanylate kinase 
PR: proline-rich 
PTK: Protein tyrosine kinase 
KD: kinase deficient 
MEF: mouse embryonic fibroblast 
EMT: epithelial-mesenchymal transition 
EGF: Epidermal growth factor 
DMEM: Dulbecco’s modified Eagle’s medium 
FBS: fatal bovine serum 
BSA: bovine serum albumin 
HRP: horseradish peroxidase 
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Ig: immunoglobulin 
ODG: n-octyl-E-D-glucoside 
NP-40: Nonidet P40 
MTT: 3-(4,5-dimethylthazol-2-yl)-2,5-diphenyltetrazolium bromide 
TAP: tandem affinity purification 
GFP: Green fluorescent protein 
GST: glutathione-S-transferase 
CBP: calmodulin binding peptide 
TEV: tobacco etch virus 
LC: liquid chromatography 
MS: mass spectrometry 
TOF: time of flight 
 
  
 
 
 
 
 
 
Chapter 1 
 
 
 
Analysis of Csk binding p62 phosphoprotein, Dok-1 
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Abstract 
The Src family tyrosine kinases (SFKs) play pivotal roles in regulating proliferation, 
differentiation and adhesion of animal cells. SFK activity is controlled by Csk 
(C-terminal Src kinase), which phosphorylates a C-terminal regulatory tyrosine residue 
of SFKs to inhibit their activities. Csk is cytoplasmic, but is recruited to sites of SFK 
activity by tyrosine-phosphorylated Csk-binding proteins. To date, several Csk-binding 
proteins, i.e. paxillin, FAK, Cbp/PAG, have been identified, but it remains possible that 
there are additional Csk-binding proteins, because SFKs have more diverse functions 
which may independently require specific Csk-binding proteins for their regulations. 
Thus I attempted to comprehensively identify Csk-binding proteins using Csk-/- MEF, in 
which the activated status of SFKs can be fixed. Herein, I identified an adaptor protein 
Dok-1 as one of the major tyrosine phosphorylated Csk-binding proteins in these cells, 
and determined the mechanism of Csk/Dok-1-mediated regulation of SFK. Tyrosine 
phosphorylation of Dok-1 is stimulated by EGF, and enhances association with Csk. In 
SFK activated cells, phosphorylated Dok-1 localizes and recruits Csk to the membrane. 
Furthermore, I demonstrate that Dok-1 can associate with not only Csk but also c-Src, 
and that these associations are essential to Dok-1’s ability to attenuate c-Src activity. 
These observations support the notion that Dok-1 function as negative feedback 
regulators of SFKs in EGF signaling. 
7 
 
Introduction 
The Src family protein tyrosine kinases (SFKs) are proto-oncogene products and play 
pivotal roles in the initiation of variety of biological process including cell proliferation, 
differentiation and adhesion (Brown and Cooper, 1996; Thomas and Brugge, 1997). The 
structural features of SFKs and an oncogenic form of c-Src (v-Src) are shown in Fig.1. 
SFKs consist of an N-terminal fatty acylation sequence that is required for membrane 
anchoring, an SH3 domain that recognizes proline-rich motifs, an SH2 domain that 
specifically binds to motifs containing phosphorylated tyrosine residue, a catalytic 
domain that includes an autophosphorylation site (Y416) in the activation loop, and a 
C-terminal regulatory region containing a negative regulatory site (Y527). The activity 
of SFKs is strictly regulated by the phosphorylation of these critical tyrosine residues: 
the autophosphorylation of Y416 is required for full activity, and the phosphorylation of 
the C-terminal Y527 induces the intramolecular interaction with the SH2 domain to 
adopt an assembled inactive conformation (Xu et al., 1997). In the oncogenic v-Src, the 
lack of the C-terminal regulatory tyrosine makes the molecule constitutively active. In 
resting normal cells, most of SFKs are present as an inactive form. In response to 
extracellular signals, SFKs become activated either by the accumulation of specific 
adapter proteins that bind to the SH2 or SH3 domain of SFKs, or by dephosphorylation 
of pY527.  
Phosphprylation of the C-terminal Y527 is catalyzed by another protein 
tyrosine kinase, C-terminal Src kinase (Csk) (Nada et al., 1991; Okada et al., 1991). 
Like SFKs, Csk consists of an SH3 domain, an SH2 domain, and a catalytic domain, but 
it lacks the N-terminal fatty acylation signal, autophosphorylation site, and the 
C-terminal regulatory site (Fig.1). Thus it belongs to an independent subfamily of 
tyrosine kinase. The critical role of Csk as a negative regulator of SFKs have been 
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demonstrated by the observation that Csk deficient mice, that die before birth, exhibit 
constitutive activation of SFKs (Nada et al., 1993). Structural analysis of Csk revealed 
that, unlike SFKs, the binding pockets of SH2 and SH3 domains of Csk are oriented 
outward, suggesting that function and/or subcellular localization can be regulated by the 
interaction with other molecules (Ogawa et al., 2002) (Fig.3). Since Csk is a 
cytoplasmic enzyme, it requires adaptor proteins to efficiently access to the 
membrane-anchored SFKs. To date, a variety of Csk-binding proteins including paxillin 
and FAK (Sabe et al., 1994), Dok-1 (Neet and Hunter, 1995), caveolin-1 (Cao et al., 
2002), LIME (Hur et al., 2003), Cbp/PAG (Brdicka et al., 2000; Kawabuchi et al., 2000), 
have been identified. These proteins interact with the SH2 domain of Csk in a 
phosphorylation-dependent manner and can concentrate Csk onto the membrane 
structures where the function and regulation of SFKs take place. Furthermore, these 
Csk-binding proteins serve as good substrates of SFKs, thereby providing a platform for 
the negative feedback loop of SFK regulation. For example, focal adhesion proteins, 
paxillin and FAK, are phosphorylated by SFK upon cell adhesion, and the 
phosphorylated molecules then recruit Csk to the focal contacts, resulting in the 
termination of SFK-mediated adhesion signaling (Fig.4). In a detergent insoluble 
membrane fractions (lipid rafts), where many signaling molecules become accumulated 
upon cell stimulation, transmembrane adaptor proteins, Cbp/PAG and LIME, serve as 
Csk anchors to terminate SFK signaling (Kawabuchi et al., 2000) (Fig.2 and 4). Like 
these examples, each Csk-binding protein functions at a specific site to regulate the 
specific and localized function of SFKs. Since SFKs have quite diverse functions, it 
seems likely that there are more Csk-binding proteins that play roles in other specific 
sites of SFK activation, such as downstream of growth factor receptors and intracellular 
organelles and/or vesicles (Fig.4). 
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Dok-1, also known as p62dok, was initially identified as a 
tyrosine-phosphorylated 62 kDa protein associated with p120RasGAP in Philadelphia 
chromosome-positive chronic myeloid leukemia blasts and in v-Abl transformed B cells 
(Carpino et al., 1997; Yamanashi and Baltimore, 1997). It later turned out to be the 
prototype member of a new adaptor protein family, referred to as the Dok (downstream 
of tyrosine kinases) family. Members of this family become phosphorylated upon 
activation of many receptor tyrosine kinases and cytoplasmic kinases, including SFKs 
(Cong et al., 1999; Jones and Dumont, 1998; Jones and Dumont, 1999; Lock et al., 
1999; Zhao et al., 2001). To date, based on amino acid sequence homology, seven 
members of the Dok family proteins have been identified; Dok-1, Dok-R (Dok-2), 
DokL (Dok-3), Dok-4, Dok-5, Dok-6, and Dok7 (Carpino et al., 1997; Cong et al., 
1999; Di Cristofano et al., 1998; Grimm et al., 2001; Jones and Dumont, 1998; Lemay 
et al., 2000; Okada et al., 2006; Yamanashi and Baltimore, 1997). Structural 
characteristics of this family make them most similar to the insulin receptor substrate 
(IRS) family of proteins (Cong et al., 1999). The Dok family of proteins contains three 
distinct protein domains or regions, which include an amino-terminal pleckstrin 
homology (PH) domain, a central phosphotyrosine binding (PTB) domain, and a 
carboxy-terminal region containing multiple tyrosine residues. Dok-1, Dok-R, and 
DokL are preferentially expressed in hematopoietic cells and have been shown to 
primarily mitigate signals downstream of a wide array of receptor and nonreceptor 
tyrosine kinases (Jones and Dumont, 1999; Nelms et al., 1998; Yamanashi et al., 2000; 
Zhao et al., 2001), while Dok-4, Dok-5 and Dok-6, preferentially expressed in neural 
cells, have been shown to potentiate signals emanating from the c-Ret receptor (Grimm 
et al., 2001). On the other hand, Dok-7 have been shown to activate MuSK, a 
muscle-specific receptor PTK, in myotubes (Okada et al., 2006), indicating that 
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Dok-family proteins are not necessarily limited to playing an adaptor function 
downstream of PTKs. It has recently been proposed that Dok family members should be 
considered as a separate subgroup of the family based upon functional differences and 
different patterns of expression (Grimm et al., 2001; Okada et al., 2006).   
In this study, to comprehensively explore Csk-binding proteins, I attempted to 
isolate Csk-binding proteins from Csk-deficient mouse embryonic fibroblasts (Csk-/- 
MEF), in which multiple SFKs are constitutively hyperactivated (Imamoto and Soriano, 
1993; Nada et al., 1994; Nada et al., 1993). Since most of Csk-binding proteins 
so-far-identified serve as excellent SFK substrates, I thought that these cells would be a 
good source of the target proteins, and that the lack of Csk would also beneficial to 
pull-down the Csk-binding proteins using exogenously added bait proteins. In this 
chapter, I describe the identification of Dok-1 as a Csk-binding protein and the 
mechanism of Csk/Dok-1-mediated regulation of SFK.  
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Materials and Methods 
Antibodies and reagents 
Anti-v-Src (Ab-1) antibody was purchased from Oncogene Research. Anti-Csk (C-20), 
anti-Dok-1 (M-276), anti-Dok-1 mAb (A-3) and anti-RasGAP mAb (B4F8) antibodies 
were from Santa Cruz Biotechnology. Anti-Csk mAb was from Transduction Lab. 
Anti-Src[pY418] and anti-Src[pY529] antibodies were from Biosource. 
Anti-phosphotyrosine (anti-pY: 4G10) was from Upstate Biotechnology. Anti-myc 
(PL14) was from MBL. Horseradish peroxidase (HRP)-conjugated anti-mouse IgG and 
anti-rabbit IgG antibody were from Zymed Laboratories, Inc. EGF was from Peprotech. 
PP2, PP3 and SU6656 were from Calbiochem. Protein inhibitors cocktail was from 
nacarai tesque. Protein G Sepharose 4 Fast Flow and glutathione Sepharose 4 Fast Flow 
were from GE Healthcare. 
 
Cell culture and transfection 
Mouse embryonic fibroblasts (MEFs) were immortalized using the simian virus 40 large 
T antigen. Csk-deficient MEFs (Csk-/- MEFs) were prepared from Csk knockout mouse 
embryos lacking both Csk and the anti-oncogene product p53, and Csk-/- cells in which 
Csk was stably re-introduced (Csk-/- + Csk MEFs) were established as described 
previously (Nada et al., 1994). All cells used in this experiments (COS7, MEFs, Csk-/- 
and Csk-/- + Csk MEFs) were maintained in Dulbecco’s modified Eagle’ medium 
(DMEM; Nissui) supplemented with 10% fatal bovine serum (FBS; Equitech-Bio, Inc.) 
at 37 °C in a humidified atmosphere containing 5% CO2. For transient expression in 
COS7 cells, pcDNA3.1 (Invitrogen) was used for the expressions of c-Src, Csk and 
Dok1-myc. pEGFP-N1 (Clontech) was used for Dok-1. Transfections were carried out 
using Lipofectamine 2000 (Invitrogen) for according to the manufacture’s instructions. 
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Immunoprecipitation 
To prepare whole cell lysates, cells were washed twice ice-cold PBS, lysed ODG buffer 
(50 mM Tris-HCl, pH7.4, 0.15 M NaCl, 5% glycerol, 1% NP-40, 2% 
n-octyl-E-D-glucoside, 1 mM EDTA, 5mM E-mercaptoethanol, 10 mM NaF, 1 mM 
Na3VO4 and protease inhibitors). After centrifugation for 30 min at 15,000 rpm, the 
supernatants were collected and measured by the Bradford method using bovine serum 
albumin (BSA) as the standard. Equal amounts of supernatants were incubated with the 
relevant antibody and Protein G Sepharose at 4 °C for 1 h. I washed the 
immunoprecipitates with ODG buffer for four times and subjected to immunoblot 
analysis.  
 
Purification of Csk SH2 domain binding proteins 
cDNA encoding SH2 domain of Csk (amino acid residue 73 to 181) and its deficient 
mutant (Csk SH2M; Arg-107 was changed to Lys) were subcloned into pGEX-6P-1 
vector. A fusion protein of GST-Csk SH2 and GST-Csk SH2M were expressed in 
Escherichia coli BL21, and coupled with glutathione-Sepharose beads. The washed 
beads were incubated with whole cell lysate at 4 °C for 1 h, and then collected by 
centrifugation. After washing for four times, the proteins complexed with GST-Csk SH2 
or GST-Csk SH2Msubjected to immunoblot analysis. 
 
Immunoblot analysis 
The whole cell lysates were mixed with equal volumes of 2 u SDS sample buffer (0.125 
M Tris-HCl, pH6.8, 4% SDS, 10% E-mercaptoethanol, 10 % Sucrose, and 0.004% 
Bromophenol blue). Immunoprecipitates and the proteins purified by GST-Csk SH2 
were mixed with 2 u SDS sample buffer equal to the volume of Sepharose resin. These 
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proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes 
(Schleicher & Schuell). Membranes were blocked with 1% BSA or 5% skim milk, 
probed with primary antibodies and further incubated with an HRP-conjugated 
secondary antibody. Antibody binding was visualized with a chemiluminescence system 
(Perkin Elmer Life Science).   
 
Growth factor stimulation 
To examine the effects of EGF stimulation, MEF cells were serum-starved overnight 
and then stimulated for the indicated time at 37 °C with 100 ng/ml EGF. Cells were 
incubated with 1 PM PP2 or DMSO for 1 h, prior to EGF stimulation.  
 
Immunofluorescence staining and conforcal microscopy 
COS7 cells co-trasfected with the pEGFP-N1 or pEGFP-Dok-1 with Csk KD (Kinase 
deficient; in which the Lys-222 ATP-binding site was changed to Arg) were grown on 
24-well plates for two days before fixation. After 24 hour, these cells were re-plated on 
collagen-coated glass coverslips. I stained Csk by immunofluorescence using Alexa 
594–conjugated anti-rabbit IgG antibody (Invitrogen). The specimens were observed 
using an OLYMPUS IX81 confocal microscope controlled by Fluoview FV1000 
software.  
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Results 
Identification of the Csk SH2 domain-associated 62 kDa protein 
To comprehensively identify Csk-binding proteins, I used Csk-/- MEFs in which SFKs 
are constitutively activated (Nada et al., 1993). As a control, Csk-/- MEFs in which Csk 
was stably re-expressed (Csk-/- + Csk MEFs) were used. Whole cell lysates from 
adhered cells (A) and suspended cells (S) were subjected to immunoblot analysis with 
an anti-phosphotyrosine (pY) (Fig.5 A). In adhered states, various SFK substrates, 
especially a120 and 65–75 kDa proteins that potentially correspond to FAK and paxillin, 
respectively, were tyrosine phosphorylated in either cell types, but with greater 
intensities in Csk-/- MEFs. When the cells were detached from the substrate, the levels 
of tyrosine phosphorylation were dramatically reduced in Csk-/- + Csk MEFs, consistent 
with the elimination of cell adhesion signaling mediated by integrin. In contrast, Csk-/- 
MEFs retained substantial levels of tyrosine phosphorylation even under suspended 
conditions. These observations represent that, in Csk-/- MEFs, SFKs are constitutively 
activated independent of extracellular stimuli, and suggest that the phosphorylation of 
potential SFK substrates that may be rapidly turned over in normal cells can be retained 
in these cells. 
Many Csk-binding proteins so-far-identified create the binding sites for Csk 
SH2 domain. Upon cell stimulation, the phosphorylated Csk binding proteins, such as 
Cbp (Kawabuchi et al., 2000), bind to the SH2 domain of Csk through specific binding 
sites (pY314 in Cbp). Thus, I first attempted to concentrate Csk-binding proteins using 
Csk SH2 domain fused to GST (GST-Csk SH2) as an affinity ligand. Pull-down analysis 
of the GST-Csk SH2 binding proteins from adhered cells revealed that several major 
tyrosine phosphorylated proteins were bound to Csk SH2 domain (Fig. 5B). Some of 
them were turned out to be well-characterized Csk-binding proteins, such as paxillin, 
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FAK and Tensin. In addition to these, I recognized that a p62 kDa phosphoprotein was 
efficiently pulled down from Csk-/- MEFs independently of cell adhesion status, 
suggesting that the p62 kDa protein would be a potential SFK substrate that recruits 
Csk.  
To identify the p62 protein, the lysates from Csk-/- MEFs cultured in adhesion 
were incubated with GST-Csk SH2, and the bound proteins were separated on a 
SDS-PAGE gel, followed research by a MALDI-TOF/MS analysis. However, I could not 
identify the 62kDa protein under these conditions (data not shown). Previous reports 
revealed that Csk binds to a p62 phosphoprotein in v-Src transformed MEFs (Neet and 
Hunter, 1995), and that the p62 protein is Dok-1 that has been originally identified as 
p120RasGAP associated protein (Carpino et al., 1997; Yamanashi and Baltimore, 1997). 
To determine the identity between the p62 phosphoprotein found in my experiments and 
Dok-1, the GST-Csk SH2 bound proteins and the immunoprecipitates with anti-Dok-1 
were immunoblotted with anti-phosphotyrosine (Fig.6, upper panel) and anti-Dok-1 
(Fig.6, middle panel). These results revealed that Dok-1 is at least a major component of 
the p62Da phosphoproteins and one of the major Csk-binding proteins in Csk-/- MEFs.  
 
Tyrosine phosphorylation of Dok-1 in EGF-stimulated mouse embryonic fibroblasts 
Dok-1 has been shown as a adaptor protein involved in the negative regulation of 
growth factor signaling (Yamanashi et al., 2000). To confirm whether Dok-1 is indeed 
tyrosine phosphorylated in response to growth factor stimulation in vivo, I determined 
the changes in tyrosine phosphorylation of Dok-1 by EGF stimulation using wild type 
mouse embryonic fibroblasts (MEFs). After EGF stimulation, the whole lysates were 
subjected to immunoblot analyses with the indicated antibodies. Tyrosine 
phosphorylation of cellular proteins including the EGF receptor and Erk1/2 were 
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increased by EGF stimulation, indicating that these cells responded to EGF stimulation 
(Fig.7 A). The activation of SFKs was also observed in response to EGF stimulation, as 
indicated by an increase in the phosphorylation of autophosphorylation site, Tyr-418 
(Fig.7 B). Dok-1 was then immunoprecipitated from the cell lysates, and the 
immunoprecipitates were subjected to immunoblotting with anti-Dok-1, 
anti-phosphotyrosine and anti-RasGAP (Fig.7 C). As expected, tyrosine phosphorylation 
of Dok-1 was transiently induced by EGF stimulation consistent with the activation of 
SFKs. These results suggest that Dok-1 is indeed tyrosine phosphorylated upon growth 
factor stimulation, and that there may be some functional link between Dok-1 
phosphorylation and SFK activations. 
 To determine if SFKs contribute to the tyrosine phosphorylation of Dok-1 in 
EGF signaling, I have examined the effects of a SFK inhibitor, PP2, on the Dok-1 
phosphorylation (Fig.8). The PP2 treatment did not inhibit activation of EGF receptor or 
ERKs, while it efficiently inhibited the phosphorylation of Dok-1. These results suggest 
that Dok-1 could serve as an in vivo substrate of SFKs.  
 
Interaction of Dok-1 with Csk under the downstream of EGF signaling 
To examine if endogenous Dok-1 could interact with endogenous Csk in vivo, I 
performed an immunoprecipitation assay from EGF treated MEFs. Whole cell lysates 
from MEFs unstimulated or stimulated with EGF were subjected to 
immunoprecipitation with anti-Dok-1 or anti-Csk, and the immunoprecipitates were 
probed with indicated antibodies (Fig.9). The results showed that Csk was 
co-immunoprecipitated with the phosphorylated Dok-1 from EGF-stimulated MEFs, 
suggesting that Csk could bind to phosphorylated Dok-1 under physiological conditions.  
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Intracellular association of Dok-1 with Csk 
To further verify the in vivo interaction of Dok-1 with Csk, the Dok-1-GFP fusion 
protein was co-expressed with a kinase deficient form of Csk (Csk KD) in COS7 cells, 
and the location of Dok-1 and Csk were observed using confocal microscopy. Since Csk 
KD serves as a dominantly negative form, Csk KD expression induced activation of 
SFKs as well as elevations of phosphorylation of their substrates, including Dok-1 (data 
not shown). As shown in Fig.10, Csk-KD was distributed broadly throughout the cells 
in GFP expressing cells, while it became co-localized with Dok-1-GFP at the plasma 
membrane in Dok-1-GFP expressing cells. These observations suggest that Dok-1 was 
able to recruit Csk to the membrane upon phosphorylation by SFKs.  
 
Csk binds to phosphorylated Tyr450 residue of Dok-1 
The precise mechanism of Csk-Dok-1 interaction was then analyzed in in vitro 
expression system using COS7 cells. Myc-tagged wild type Dok-1 (W) or its mutant 
with a Tyr to Phe substitution at the potential Csk binding site Y450 (YF) (Neet & 
Hunter, 1995) were transiently expressed with or without c-Src in COS7 cells, and 
whole cell lysates were analyzed by immnunoblotting (Fig.11 A). Interestingly, it was 
found that the co-expression with Dok-1 greatly enhanced the tyrosine phosphorylation 
of cellular proteins, potentially reflecting that Dok-1 could activate c-Src. 
Immnuprecipitation assay with anti-myc showed that tyrosine phosphorylation of either 
type of Dok-1 was greatly enhanced by c-Src expression and that only wild type Dok-1 
was co-immunoprecipitated with Csk (Fig.11 B). The inverse assay with anti-Csk also 
confirmed that wild type Dok-1, but not the YF mutant, was co-immunoprecipitated 
with Csk. These results demonstrate the phosphorylation of Y450 of Dok-1 is required 
for the interaction with Csk.    
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Contribution of Dok-1 to the regulation of SFKs activities 
Finally, I examined the role of Dok-1 in the regulation of SFK activity. COS7 cells were 
co-transfected with c-Src and Mock vector (-), myc-tagged wild type Dok-1 (W) or its 
Y450F mutant (YF) (Fig.12 A), and the Dok-1 immunoprecipitates were then probed 
with indicated antibodies (Fig.12 B). It was shown that wild type Dok-1 could 
simultaneously interact with c-Src and Csk, and the phosphorylation of the C-terminal 
Y529 of c-Src was enhanced as a result of the close interaction with Csk on the same 
Dok-1 molecule. In contrast, the Y450F mutant did not interact with Csk, resulting in a 
reduced phosphorylation at Y529 of c-Src. These was no significant change in the 
binding to RasGAP between wild type and Y450F mutant, indicating the specific role of 
Y450 in the regulation of Csk. These data suggest that phosphorylated Dok-1 could 
simultaneously bind to c-Src and Csk to allow close interaction between enzyme and 
substrate, thereby efficiently terminating c-Src mediated cell signaling. 
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Discussion 
In this chapter, I describe the identification and characterization of Dok-1 as a major 
Csk-binding protein that play roles in the regulation of SFK in EGF signaling. 
Previously, it was already shown in v-Src transformed MEFs that Csk binds to a p62 
phosphoprotein (Neet and Hunter, 1995), which later turned out to be Dok-1 that was 
originally identified as p120RasGAP associated protein (Carpino et al., 1997; Yamanashi 
and Baltimore, 1997). However, the role of Dok-1 in the regulation of SFK function has 
remained thoroughly unknown. In this study, I clearly showed that, once phosphorylated 
by SFK, Dok-1 binds to SFK and Csk to provide a platform where Csk-mediated 
inactivation of SFK can be efficiently performed (Fig.13). These observations are well 
consistent with the recent reports on Dok-1 and Dok-R from other groups. Dok-1 is 
shown to independently attenuates ERK pathway and Src/c-Myc pathway to inhibit 
PDGF signaling (Zhao et al., 2006), and Dok-R attenuates EGF-ERK pathway and Akt 
activation through processive recruitment of c-Src and Csk (Van Slyke et al., 2005). It is 
thus conceivable that Dok-1 is involved in the Csk-mediated SFK regulatory circuit. 
 The Dok family of proteins contains multiple domains and regions, which 
include a PH domain, a PTB domain, and a carboxy-terminal region containing multiple 
tyrosine residues. These domains and regions can mediate various combinations of 
protein-lipid and protein-protein interactions, indicating that Dok-1 could serve as a 
central hub of the cell signaling. Dok-1 subfamily (Dok-1, Dok-R and Dok-L) has?
been shown to primarily mitigate signals downstream of a wide array of receptor and 
nonreceptor tyrosine kinases (Jones and Dumont, 1999; Lemay et al., 2000; Mustelin 
and Tasken, 2003; Yamanashi et al., 2000). The interaction of membrane bound Dok-1 
with RasGAP has been shown to play critical roles in suppressing growth factor singling. 
However, I observed that the Dok-1-RasGAP interaction was unchanged by EGF 
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stimulation, while Dok-1-Csk interaction was readily and transiently detected in early 
stages of cell stimulation consistent with the activation profile of SFKs. These suggest 
that Dok-1-Csk mediated SFK regulation system would largely contribute to the 
downregulation of EGF signaling at least in MEFs.  
Upon cell stimulation, SFKs are transiently activated in the early phase of cell 
signaling. For example, SFK activity reaches maximal within 1 min after EGF 
stimulation, then it is rapidly downregulated within 5 min. From these features of SFKs, 
it has been difficult to capture the protein-protein interaction that is transiently formed 
during these short-term events. Therefore, for the study of molecular mechanism of 
function and regulation of SFKs, constitutively active forms of SFKs, such as v-Src and 
a mutated c-Src with a Tyr to Phe substitution at the C-terminal regulatory site Y527, 
has been widely used (Brown and Cooper, 1996; Frame et al., 2002). However, the 
overexpression of these active forms induces unusually high levels of tyrosine 
phosphorylation of various proteins, leading to strong cell transformation. Thus, to 
identify physiologically significant targets of SFKs that potentially bind to Csk, I here 
employed Csk-/- MEFs in which endogenous SFKs are constitutively activated by the 
reduced phosphorylation at the C-terminal regulatory site (Nada et al., 1994). These 
cells contain relatively high level of tyrosine phosphorylated proteins and some SFK 
signaling pathways were augmented, such as those involved in cell adhesion and 
cytoskeletal organization (Yagi et al., 2007). However, these cells do not show 
transformed phenotype. Based on these, I thought that the activated status of 
endogenous SFKs is fixed by the lack of Csk in Csk-/- MEFs, which would be beneficial 
conditions to capture the SFK substrates waiting for the recruitment of Csk. In this study, 
the pull-down assay using GST-Csk SH2 successfully identified not only previously 
characterized Csk-binding proteins but also Dok-1 that had not been detected in normal 
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cells. The further study using Csk-/- MEFs would give more information about the 
function and regulation of SFKs. 
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Figure 1. Domain structures of SFKs and Csk
Schematic models of domain structures of c-Src, v-Src and Csk are shown. All three 
proteins consist of a Src homology 3 (SH3), a Src homology 2 (SH2) domain and a 
catalytic domain. However, Csk lacks characteristic features conserved in SFKs, that 
include the N-terminal fatty acylation signal, the autophosphorylation site (Y416) in the 
catalytic domain, and the C-terminal negative regulatory site (Y527). v-Src lacks the 
C-terminal negative regulatory region, and instead contains unrelated 12 amino acids from 
virus gene and several point mutations throughout the molecule.
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Figure 2. Regulation mechanism of Src family tyrosine kinases
Most of SFK members are preferentially localized in lipid rafts where a variety of signaling 
molecules, including Cbp, are concentrated. Under resting conditions, SFKs are present as 
an inactive form with a closed conformation. In response to extracelluar stimuli, SFKs 
become activated by displacement of inhibitory molecular interactions through binding to 
some adaptor proteins or by dephosphorylation of C-terminal tyrosine residue (Y527). Full 
activation involves autophosphorylation of tyrosine residue in the activation loop of SFKs 
(Y416). Activated SFKs phosphorylate several substrates, including Cbp, which induces 
recruitment of Csk to lipid rafts to allow the close interaction between SFK and Csk. The 
C-terminal tyrosine of SFKs is phosphorylated by Csk, which again induces the 
intramolecular domain interactions, resulting in a closed “inactive” conformation.
28
Figure 3. Regulation of Csk kinase activity 
Schematic model of the structures of Csk. The crystal structure of Csk reveals that Csk has 
two different conformations, the active and the inactive forms. The SH2 domain of active 
and inactive molecules are shown in blue and red, respectively (left). Binding of a strong 
ligand, such as the phosphorylated Cbp/PAG, to the SH2 domain could elicit potentially 
full activity of Csk
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Figure 4. The diverse SFK functions are regulated by Csk via site specific 
adapter molecules
The kinase activity of SFKs is negatively regulated by the phosphorylation of a C-terminal 
regulatory Tyr by Csk. Since Csk is a cytoplasmic enzyme, it exploits adaptor proteins to 
efficiently access to the membrane-anchored SFKs. A variety of Csk-binding proteins, 
including paxillin, FAK and Tensin in focal adhesion, and Cbp and LIME in lipid rafts, 
have been identified. The SFK functions at specific sites are regulated via these site specific 
adapter molecules.
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Figure 5. Interaction of Csk SH2 domain with phosphoproteins in Csk-/- 
MEFs
A. Monolayer cultures of Csk-/- MEFs and Csk-/- + Csk MEFs were lysed with ODG buffer 
(A: adhered cells). The monolayer cultures were trypsinized, resuspended and held in 
suspension at 37 ° C for 1 h. These cells were collected and lysed with ODG buffer (S: 
suspended cells).  The samples were resolved by SDS-PAGE and analyzed by 
immunoblotting with anti-phosphotyrosine (pY). B. Association of GST-Csk SH2 with 
62kDa phosphoprotein in Csk-/- MEFs. The samples pulled-down with GST-Csk SH2 were 
immunoblotted with anti-phosphotyrosine (pY).
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Figure 6. Dok-1 is a major component of p62 phosphoproteins
Whole cell lysates of Csk-/- MEFs were subjected to pull-down assay using GST fusion 
proteins fused to wild-type Csk SH2 or SH2 R107K mutant (SH2M). Dok-1 was 
immunoprecipitated from these cells. The precipitated samples were analyzed by 
immunoblotting with anti-phosphotyrosine and anti-Dok-1. Locations of identified proteins 
are shown on the right of the panel.
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Figure 7. EGF stimulation of MEFs induces Dok-1 phosphorylation
A. and B. MEFs were starved overnight in serum-free DMEM, and then incubated with 
100 ng/ml EGF for the indicated periods. The cells were lysed with ODG buffer, followed 
by immunoboloting with anti-phosphotyrosine (pY; A) and the indicated antibodies (B). C. 
Immunoprecipitated Dok-1 was subjected to imunoblotting with anti-pY, anti-Dok-1 
anti-RasGAP.
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Figure 8. Inhibition of SFK activity reduces Dok-1 phosphorylation
Serum starved MEFs were pre-incubated with 5 µM PP2 or DMSO for 1 h and then 
stimulated with 100 ng/ml EGF for the indicated periods. Whole cell lysates (upper panel) 
and the immunoprecipitated Dok-1 (middle panel) were immunoblotted with the anti-pY. 
Dok-1 protein in the immunoprecipitate was confirmed by immunoblotting with anti-Dok-1
(lower panel).
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Figure 9. Interaction of Dok-1 with Csk in EGF stimulation
Serum starved MEFs were pre-incubated with 5 µM PP2 or DMSO for 1 h and then 
stimulated with 100 ng/ml EGF for 1 min. Dok-1 and Csk were immunoprecipitated, and 
the complexes were immunoblotted with pY, anti-Dok-1 and anti-Csk.
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Figure 10. Co-localization of Dok-1 with Csk in COS7 cells
COS7 cells were transiently co-transfected with the vectors encoding Csk and GFP (upper 
panels) or Dok-1-GFP (lower panels). After 48 h, the cells were fixed and Csk was 
immunostained with anti-Csk antibody coupled with Alexa 594-conjugated goat anti-rabbit 
antibody (red). Dok-1 was located by GFP signals (green). Merged images are also shown 
(yellow). In COS7 cells, the level of endogenous Dok-1 in COS7 cells was negligible 
compared with that of exogenously expressed Dok-1-GFP.
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Figure 11. Interaction of Dok-1 with Csk via pY450
A. COS7 cells were transfected with the indicated combinations of the expression vectors, 
and the whole cell lysates were immunoblotted with anti-pY, anti-myc and anti-Csk. (-): 
Mock, W: wild-type, YF: Y450F mutant. B. Dok-1-myc (left panels) and Csk (right panels) 
were immunoprecipitated, and the complexes were immunoblotted with anti-pY, anti-myc 
and anti-Csk.
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Figure 12. Interaction of Csk with Dok-1 regurates Src kinase activity
A. COS7 cells were transfected with the indicates combinations of the expression vectors, 
and the whole cell lysates were immunoblotted with anti-myc, anti-Src and anti-Csk. (-): 
Mock, W: wild-type, YF: Y450F mutant. B. Dok-1-myc was immunoprecipitated, and the 
complexes were immunoblotted with the indicated antibodies.
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Figure 13. Dok-1 regulates Src activity through processive recruitment of 
Src and Csk
Src is tightly and dynamically maintained between active (pY416) and inactive (pY527) 
conformation. In the absence of growth factor stimulation (ex. EGF stimulation), a portion 
of Src constitutively interacts with Dok-1. On growth factor stimulation, Src is activated 
and phosphorylates Dok-1. Phosphorylated Dok-1 interacts with Src via SH3 or SH2 
domain, where a transient Src hyperactivation occurs. Src dependent phosphorylation of 
Dok-1 Y450 facilitates the recruitment of Csk and subsequent inhibition of Src kinase 
activity.
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Chapter 2 
 
 
 
Proteomic analysis of novel Csk binding proteins 
involved in the regulation of c-Src transformation 
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Abstract 
In Chapter 1, I identified Dok-1 as a scaffolding molecule for SFKs and Csk, and 
showed that Dok-1 regulates SFKs activity downstream of EGF receptor. In this chapter, 
to further elucidate the role of Csk-mediated SFK regulatory system, I explored more 
widely the scaffolding proteins for SFKs and Csk that are potentially involved in the 
regulation of cell transformation induced by c-Src. For this, I performed a proteomic 
analysis of tyrosine phosphorylated proteins that interact with c-Src and/or Csk. The 
c-Src interacting proteins were affinity-purified with Src SH2 domain from Src 
transformed cells. LC-MS/MS analysis identified several Src substrates, such as focal 
adhesion kinase, paxillin and ZO-1/2, as a transformation-dependent Src target. The Csk 
binding proteins were analyzed by a tandem affinity purification method (TAP). In 
addition to the previously identified Csk binding proteins, including Cbp/PAG, paxillin, 
and caveolin-1, I found that ZO-1/2 could also serve as a major Csk binding protein. 
ZO-2 was phosphorylated concurrently with Src transformation and specifically bound 
to Csk in a Csk SH2 dependent manner. These results suggest novel roles for ZO 
proteins as Src/Csk scaffolds potentially involved in the regulation of Src 
transformation. 
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Introduction 
c-Src, a non-receptor tyrosine kinase, is the cellular prototype of v-Src, an oncogene 
product of Rous sarcoma virus (Takeya and Hanafusa, 1983). Since c-Src is frequently 
overexpressed and activated in a wide variety of advanced human cancers, such as colon 
and breast cancers, it has been implicated in malignant conversion in human cancers 
(Ishizawar and Parsons, 2004; Yeatman, 2004). Numerous studies have shown that the 
activation of c-Src induces the tyrosine phosphorylation of various cellular proteins 
including focal adhesion kinase (FAK) (Hanks and Polte, 1997), Cas and Crk (Sakai et 
al., 1994), Shc (Verderame et al., 1995), phosphatidyl inositol 3 kinase (PI3K) (Penuel 
and Martin, 1999), and signal transducers and activators of transcription 3 (STAT3) (Yu 
et al., 1995), resulting in the activation of signaling pathways associated with cancer 
progression. However, the complexity of these c-Src pathways have made it difficult to 
elucidate which pathways are critical for c-Src induced cell transformation and how 
these pathways are suppressed in normal cells.  
The kinase activity of c-Src is negatively regulated by the phosphorylation of a 
C-terminal regulatory Tyr by C-terminal Src kinase (Csk) (Nada et al., 1991; Nada et al., 
1993). Since Csk is a cytoplasmic enzyme, it exploits adaptor proteins to efficiently 
access to the membrane-anchored c-Src and its relatives (Src family kinases; SFKs). To 
date, a variety of Csk-binding proteins including paxillin and FAK (Sabe et al., 1994), 
Dok-1 (Neet and Hunter, 1995), LIME (Hur et al., 2003), caveolin-1 (Cao et al., 2002), 
and Cbp/PAG (Brdicka et al., 2000; Kawabuchi et al., 2000), have been identified. 
Furthermore, it has been shown that these Csk scaffold proteins could serve as 
substrates of SFKs by directly interacting with SFKs. These observations suggest that 
the diverse SFK functions are precisely regulated by Csk on a variety of Csk scaffold 
proteins whose expressions are temporally and spatially regulated within the cells. 
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However, it remains unclear which Csk scaffold proteins are involved in the regulation 
of the transforming ability of c-Src.  
To address the regulatory mechanism of Src induced cell transformation, I here 
adopted a proteomic analysis of phosphoproteins that interact with c-Src and/or Csk in 
Src transformed cells. Recently, we have developed an experimental system using 
Csk-deficient mouse embryonic fibroblasts (Csk-/- MEF), in which wild-type c-Src can 
induce cell transformation (Oneyama et al., 2008). Using this system, I identified zona 
occludens-1/2 (ZO-1/2) as a new Src/Csk scaffolding protein that is potentially involved 
in the regulation of c-Src transformation. 
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Materials and Methods 
Cell culture and retroviral-mediated transfection 
Csk-/- and sibling Csk+/+ MEFs immortalized using the simian virus 40 large T antigen 
were kind gifts of from Dr. Akira Imamoto (Thomas et al., 1995). These cells were 
cultured in DMEM supplemented with 10% FBS. All of the gene transfer experiments 
were carried out by using retroviral vectors, pCX4, as described previously (Akagi et al., 
2003; Oneyama et al., 2008). Retroviral vectors encoding wild-type chicken c-Src and 
its constitutively active form (c-SrcYF) were kindly provided by Dr. Tsuyoshi Akagi. 
Wild-type rat Csk was expressed using a retroviral vector pCX4bleo. For transient 
expression in HEK293T cells, pcDNA3.1 (Invitrogen) was used for the expressions of 
c-Src, Csk, and Csk-HA. pCMV-Tag-1 (STRATAGENE) and pFLAG-CMV-2.1 
(SIGMA) were used for ZO-2-myc and FLAG-ZO-2, respectively. Transfections were 
carried out using Lipofectamine 2000 (Invitrogen). 
 
Immunochemical analysis and F-actin staining 
Immunoblotting and immunoprecipitation were performed as described previously 
(Shima et al., 2003). The following antibodies were used: anti-phosphotyrosine 
(anti-pY: 4G10, Upstate), anti-PELP1 (Bethyl), anti-ZO-2 (Zymed), anti-FAK (C-20, 
Santa Cruz), anti-Cas (BD Biosciences), anti-GIT1 (H-170, Santa Cruz), anti-cortactin 
(Upstate), anti-Sam68 (C-20, Santa Cruz), anti-paxillin (Transduction Lab.), anti-Csk 
(C-20, Santa Cruz), anti-Csk mAb (Transduction Lab.), anti-myc (PL-14, MBL), 
anti-HA (Zymed), and anti-FLAG (M2, SIGMA). For F-actin staining, the fixed cells 
were stained with Alexa 594-phalloidin as described previously (Oneyama et al., 2008).  
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Soft-agar colony-formation assays 
Single-cell suspensions of 4 u 104 cells were plated per 60-mm culture dish in 3 ml of 
DMEM containing 10 % FBS and 0.36 % agar on a layer of 5 ml of the same medium 
containing 0.7 % agar. Two weeks after plating, colonies were stained with 
3-(4,5-dimethylthazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). 
 
Purification of Src SH2 domain binding proteins 
Detergent soluble (non-Raft) fractions form Src transformed cells were prepared as 
described previously (Shima et al., 2003). Briefly, cells were lysed in a buffer (0.25% 
Triton X-100, 50 mM Tris-HCl (pH 7.4), 0.15 M NaCl, 1 mM EDTA, 25 mM NaF, 1 
mM Na3VO4 and protease inhibitors), and separated by ultracentrifugation on a 
discontinuous sucrose gradient (5%-35%-40%). The heavy fractions containing 40% 
sucrose were collected and used as non-Raft fractions. A fusion protein of Src SH2 
domain with GST (GST-Src SH2) was expressed in Escherichia coli BL21 using 
pGEX-6P-1 vector, and coupled with glutathione-Sepharose beads (GE Healthcare). 
The washed beads were incubated with non-Raft fractions at 4 °C for 2 h, and then 
collected by centrifugation. After extensive washing, the proteins complexed with 
GST-Src SH2 were eluted with 20 mM glutathione. 
 
Tandem affinity purification of Csk binding protein 
For tandem affinity purification (TAP) (Fig.1) of Csk binding protein, a kinase-deficient 
Csk (K222R) which was tandemly tagged at its C-terminus with an immunoglobulin G 
(IgG)-binding units of protein A from Staphylococcus aureus, a cleavage site for the 
tobacco etch virus (TEV) protease and a calmodulin binding peptide (CBP) 
(Burckstummer et al., 2006), was stably expressed in Csk-deficient cells using 
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pCX4bleo vector. The cells were lysed in ODG buffer (50 mM Tris-HCl, pH 7.4, 0.15 
M NaCl, 10% glycerol, 1% NP-40, 2% n-octyl-E-D-glucoside, 1 mM EDTA, 5 mM 
E-mercaptoethanol, 10 mM NaF, 1 mM Na3VO4 and protease inhibitors), and the 
cleared lysates were incubated with rabbit-IgG Sepharose (GE Healthcare) at 4 °C for 2 
h. The beads were washed with ODG buffer and then with TEV-protease cleavage 
buffer (10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5 mM EDTA, 0.1% NP-40 and 1 
mM DTT) and the bound proteins were eluted by addition of TEV protease (16 °C for 1 
h). The cleaved product was then incubated with calmodulin Sepharose (GE Healthcare) 
in the presence of 2 mM CaCl2, and the bound proteins were eluted with EGTA. 
 
Sample preparation and LC-MS/MS analysis 
The purified protein complexes were separated by SDS-PAGE on a 10%T gel. After 
visualization of the proteins by silver staining, specific bands and/or regions of interest 
were excised from the gel and digested in situ with Achromobacter protease I (Lys-C) 
(Wako, Osaka) or TrypsinGold (Promega) essentially as described (Shevchenko et al., 
1996). The digested samples were analyzed by nanocapillary reversed-phase 
LC-MS/MS using a C18 column (I 75 Pm) on a nanoLC system (LC Packing) coupled 
to a quadrupole time-of-flight mass spectrometer (QTOF Ultima, Waters). Direct 
injection data-dependent acquisition was performed using one MS channel for every 
three MS/MS channels and a dynamic exclusion for selected ions. Proteins were 
identified by database searching (Mascot Daemon, Matrix Science). Search parameters 
were as follows: MS tolerance of 0.2 Da, MS/MS tolerance of 0.4 Da, protease 
specificity allowing for one missed cleavage site, fixed modification of 
carbamidomethylation of cysteine residues, variable modification of oxidation of 
methionine residues, and variable modification of phosphorylation of tyrosine residues.  
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Results 
c-Src induced transformation of Csk-deficient fibroblasts 
Recently, we have developed an experimental system using Csk-deficient mouse 
embryonic fibroblasts (Csk-/-), in which wild type c-Src can induce cell transformation 
(Oneyama et al., 2008) (Fig.2). Using the Csk-/- cells, we established a series of cell 
lines with different transformed phenotypes (Fig.2). Csk-/- cells had elevated levels of 
tyrosine phosphorylation of cellular proteins compared with Csk expressing cells, but 
were not sufficient for cell transformation (Oneyama et al., 2008). Overexpression of 
c-Src induced further elevation of tyrosine phosphorylation and transformed the cell. 
Expression of constitutively active form of c-Src, that has a Tyr to Phe substitution at 
the regulatory site (c-SrcYF), induced dramatic elevation of tyrosine phosphorylation 
concurrent with cell transformation(Fig.2 and 3). By comparing these cell lines, I first 
attempted to identify the critical c-Src targets required for cell transformation.  
It is known that substantial fractions of c-Src and other SFK members are 
localized in a membrane microdomain, lipid raft, via their N-terminal fatty acid moiety 
(Galbiati et al., 2001). However, the elevation of tyrosine phosphorylation of raft 
proteins was not so remarkable as those in non-raft fractions (Fig.3). Furthermore, our 
recent analysis suggested that the transforming ability of c-Src is rather suppressed 
when c-Src is localized in rafts (unpublished observation). In this study, I thus focused 
on tyrosine phosphorylated proteins present in non-Raft fractions. 
 
Identification of Src SH2 interacting proteins 
To identify the critical Src targets in transformed cells, I first attempted to identify the 
Src interacting proteins. To evaluate the role of c-Src in cell transformation, I have 
recently developed an experimental system using Csk-deficient mouse embryonic 
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fibroblasts (Csk-/-), in which c-Src can induce cell transformation (Oneyama et al., 
2008). In this study, I used Csk-/- cells overexpressing c-Src or an active form of c-Src 
with a Tyr to Phe substitution at the regulatory site (c-SrcYF) as Src transformed cells. 
It is known that substantial fractions of c-Src are localized in a membrane microdomain, 
lipid rafts (Galbiati et al., 2001). However, as our recent analysis suggested that the 
localization of c-Src in non-raft compartments is critical for cell transformation 
(unpublished observation), I used non-raft fractions as starting materials. The non-raft 
fractions prepared from Src transformed cells were incubated with GST-Src SH2, and 
the bound proteins were separated on a SDS–PAGE gel (Fig.4 A). The LC–MS/MS 
analysis of the visible bands resulted in the identification of whole 24 proteins (data not 
shown). The representative proteins are shown on the right of the panel (Fig.4 A), and 
the identities of some representative proteins were confirmed by immunoblotting (Fig.4 
B). A representative MS/MS spectrum assigned to ZO-2 is shown in Fig.5.  
The identified proteins included well-characterized major Src targets, such as 
FAK, Cas, cortactin, Sam68, paxillin, and GIT1, indicating that our experimental 
system was functional. In addition to these, I identified poorly characterized Src targets, 
some of which are potentially involved in the Src signaling. Of these candidates, I 
identified ZO-1/2 as a Src interacting protein which was specifically detected in 
transformed cells (Fig.4 A and B). The tyrosine phosphorylation of ZO-1/2 by v-Src has 
been previously observed (Kaihara et al., 2003; Takeda and Tsukita, 1995), but its 
precise role in cell transformation still remains unclear. ZO-1/2 is a 
membrane-associated guanylate kinase (MAGUK) protein composed of three PDZ 
domains, an SH3 domain, a GuK domain, and an actin binding proline-rich domain 
(Fig.10) (Gonzalez-Mariscal et al., 2000). The PDZ1 domain and the GuK domain bind 
to claudins and occludens, respectively, indicating its critical roles as tight junction 
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proteins in epithelial cells (Umeda et al., 2006). However, it is also known that 
SH3-GuK domains are responsible for the binding to α-catenin and the proline-rich 
domain binds to actin filaments; these implicate the role for ZO proteins in the 
regulation of cadherin-based cell adhesion as well as cytoskeletal organization (Itoh et 
al., 1997). These observations suggest that ZO-1/2 would play crucial roles in the 
regulation of cell transformation.  
 
Identification of Csk binding proteins 
On the other hand, it is also known that the critical Src targets can interact with the Src 
inhibitor Csk. Csk contains an SH2 and an SH3 domains (Fig.6 A), and the SH2 domain 
is shown to interact with tyrosine phosphorylated Src targets (Sabe et al., 1994). 
Recruitment of Csk to the Src targets is believed to be critical for the efficient 
termination of the Src signaling. In this context, I next analyzed Csk binding proteins to 
identify functional Src targets. To comprehensively explore the proteins that specifically 
bind to Csk in the cells, I adopted a tandem affinity purification (TAP) method (Fig.1 
and 6 A). To maintain the active state of c-Src in the transformed cells, I introduced a 
kinase-deficient form of tagged Csk (CskKD-TAP) or its mutant (SH3/2mt-TAP) in 
either non-transformed or c-Src transformed cells (Fig.6 B).  
The Csk complexes were purified by a sequential column chromatography, and 
were separated by an SDS–PAGE (Fig.6 B, left panel). Immunoblot analysis showed 
that the Csk complex from c-Src transformed cells gave some specific tyrosine 
phosphorylated proteins, suggesting that there are some Csk binding proteins involved 
in cell transformation (Fig.6 B, right panel). The LC–MS/MS analysis of the 
silver-stained bands resulted in the identification of listed proteins that include known 
Csk binding proteins, such as Tensin, paxillin, Cbp, and caveolin-1 (Fig.7 and 
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Supplementary Data). In addition, we also identified ZO-1/2 as a major Csk binding 
protein (Fig.7 and S1) that corresponds to the tyrosine phosphorylated protein detected 
specifically in c-Src transformed cells (Fig.6 B). These results together with the 
identification of ZO-1/2 as a Src interacting protein raised the possibility that ZO-1/2 
would be a critical scaffolding protein for the Src/Csk regulatory circuit. 
 
Interaction of ZO-2 with Csk 
To address the role of ZO-1/2 in cell transformation, the tyrosine phosphorylation status 
of ZO-2 was compared between transformed and non-transformed cells (Fig.8 A). ZO-2 
in the cells transformed by c-Src or c-SrcYF gave stronger tyrosine phosphorylation 
signals compared with non-transformed cells, indicating the potential correlation of 
ZO-2 phosphorylation with cell transformation. The phosphorylation of ZO-2 in Src 
transformed cells was further confirmed in Csk-/- cells expressing Csk and c-SrcYF 
(Fig.8 B). Concurrent with transformation by c-SrcYF, Csk bound to various Src targets 
and ZO-2 became efficiently tyrosine phosphorylated. The interaction between ZO-2 
and Csk was examined by an expression system using HEK293 T cells. Ectopically 
expressed ZO-2 was efficiently tyrosine phosphorylated by the expression of c-SrcYF 
(Fig.9 A). Immunoprecipitation assay showed that wild-type Csk (W) or its SH3 mutant 
(3M) was co-precipitated with ZO-2, whereas its SH2 mutant (2M) was less effectively 
co-precipitated (Fig.9 B). These observations demonstrate that ZO-2 binds to Csk in a 
manner dependent on the Csk SH2 domain. 
 
Csk binding regions in ZO-2 
Next, the interaction between ZO-2 and Csk was further examined using a series of 
ZO-2 deletion mutants (Fig.10). Full-length ZO-2, the fragment a (a.a. 4–652), and the 
51 
 
fragment e (a.a. 487–1167) were tyrosine phosphorylated (Fig.11, right middle panel) 
and co-immunoprecipitated with Csk (right bottom panel). These observations suggest 
that Csk binds to ZO-2 via the region containing Tyr 554, 575, and 618 (Fig.10, gray 
boxed). However, point mutagenesis studies showed that a single Tyr to Phe mutation of 
these residues did not affect the tyrosine phosphorylation of ZO-2 or the interaction 
with Csk, suggesting the redundant role of these residues in the interaction with Csk 
(data not shown). Although the most critical binding sites are yet to be determined, 
these results demonstrate that Csk could directly and specifically interact with ZO-2 in 
the cells. 
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Discussion 
In this study, I have identified ZO-1/2 as a new scaffold for Src/Csk in Src transformed 
cells. The correlation between ZO-2 phosphorylation and Src transformation raised the 
possibility that the recruitment of Csk to ZO proteins might be involved in the 
suppression of transforming activity of c-Src. Many other Src target proteins including 
paxillin, FAK, Tensin, caveolin-1, LIME, and Cbp, have been shown to have the similar 
system. These molecules are tyrosine phosphorylated in accordance with the activation 
of c-Src and subsequently create the binding site for Csk. The recruited Csk inactivates 
c-Src on the scaffold proteins to efficiently terminate the c-Src signaling. These Csk 
scaffolds have unique localizations in the cells. Paxillin, FAK, and Tensin are localized 
to focal adhesions, while caveolin-1, LIME, and Cbp are exclusively localized in 
cholesterol-enriched membrane microdomain, caveolae or lipid rafts (Galbiati et al., 
2001). As these intracellular domains have been shown as the origins of the Src 
signaling, the Csk scaffold proteins present in these domains are critical regulators of 
Src-mediated cell responses. In this context, ZO proteins should also play roles as 
another regulator of c-Src acting at a specific domain such as cell–cell junction. The 
activity of c-Src has been implicated in the regulation of epithelial-mesenchymal 
transition (EMT), which is a critical process of cancer progression (Frame, 2004; 
Rengifo-Cam et al., 2004). Since ZO proteins have been shown to interact not only with 
tight junction but also with adherence junction and actin filaments (Itoh et al., 1997), it 
is likely that ZO proteins contribute to the regulation of the multiple steps of EMT, that 
include cell–cell adhesion in epithelial cells and cytoskeletal remodeling in 
mesenchymal cells. Indeed, although the effect was not so remarkable, tyrosine 
phosphorylation of ZO proteins by v-Src has been shown to weaken junctional sealing 
(Takeda and Tsukita, 1995). A unique role of ZO-1 in regulating gene expression 
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associated with tumor invasion has also been reported (Polette et al., 2007). The more 
detailed analyses of the functions of ZO proteins as Src/Csk scaffolds would provide 
new clues to understanding the regulatory mechanisms of cancer progression 
particularly mediated by c-Src activation. 
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Figure 1. Principle of the TAP strategy
Tandem affinity purification (TAP) method is useful for the determination of protein 
partners quantitatively in vivo. The TAP tag used in this study consists of calmodulin 
binding peptide (CBP) from the N-terminal, followed by tobacco etch virus protease (TEV 
protease) cleavage site and Protein A, which binds tightly to IgG. The procedure is as 
follows; The TAP fused bait protein with the other constituents is collected by means of an 
IgG beads. After washing, TEV protease is introduced to release the bound material at the 
TEV protease cleavage site. This eluate is then incubated with calmodulin-coated beads in 
the presence of calcium. This second affinity step is required to remove the TEV protease 
as well as traces of contaminants remaining after the first affinity step. After washing, the 
bound material is then eluted with EGTA. The native elution consisting of the bait protein 
and its interacting protein partners is analyzed by SDS-PAGE, followed by the 
identification with mass spectrometry.
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Figure 2. c-Src induced transformation of Csk-deficient fibroblasts
Csk+/+ mouse embryonic fibloblasts (Csk+/+ MEFs) and Csk-/- MEFs were infected with a 
retrovirus carrying c-Src. Stable cell lines were selected by treatment with puromycin. Cell 
morphologies were observed under phase contrast microscopy (left panels).The fixed cells 
were stained for F-actin with Alexa 594-phalloidin, and observed under confocal 
microscopy (middle panels). Transforming ability was examined by soft-agar colony 
formation assay (right panels). Cells (4 × 104) were plated in soft agar, and after 2 weeks, 
colonies were stained with MTT reagent and photographed.
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Figure 3. Tyrosine phosphorylation of cellular proteins in various cell 
types
Csk-/- MEFs were infected with the indicated retrovirus vectors. Whole cell lysates of the 
stable transfectants were immunoblotted with anti-phosphotyrosine (pY).
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Figure 4. Identification of Src SH2 interacting proteins
A. The non-raft fractions were prepared form Src transformed Csk-/- cells, and the tyrosine 
phosphorylated proteins were detected with anti-pY (left panel). The samples pulled down 
with GST-Src SH2 were immunoblotted with pY (middle panel) and stained with silver 
(right panel). The locations of some identified major proteins are indicated on the right of 
the panel. B. The pull-down samples were immunoblotted with the antibodies to the 
indicated proteins.
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Figure 5. Identification of Src SH2 interacting proteins
A representative MS/MS spectrum assigned to ZO-2 is shown.
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Figure 6. Identification of Csk binding proteins
A. A schematic representation of the kinase-deficient form of tagged Csk (CskKD-TAP). 
CBP, a calmodulin binding peptide; TEV, a cleavage site for the TEV protease. B. Csk 
binding proteins were purified by TAP method from Csk-/- cells transfected with 
CskKD-TAP (lane 1), c-Src plus Csk mutant (SH3/2mt-TAP) (lane 2), or c-Src plus 
CskKD-TAP (lane 3). The purified Csk complex was separated on a SDS–PAGE gel, 
followed by silver staining (left panel) and immunoblotting with anti-pY (right panel). 
Arrows indicate the locations of proteins that were specifically detected in c-Src 
transformed cells.
63
A
SH2SH3 Kinase CBP TEV ProteinA
K222RW47A R107K
B
Silver stain
Csk
+ c-Src
Cs
kK
D-
TA
P
SH
3/2
mt
-T
AP
Cs
kK
D-
TA
P
+ c-Src
Cs
kK
D-
TA
P
SH
3/2
mt
-T
AP
Cs
kK
D-
TA
P
200
116
97
66
45
(kDa)
IB: pY
29
Figure 7. Identification of Csk binding proteins
Csk binding proteins purified by a larger scale of TAP method were detected by silver
staining. Proteins identified by LC–MS/MS analyses are indicated.
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Figure 8. Phosphorylation of ZO-2 in transformed and non-transformed 
cells
A. Endogenous ZO-2 was immunoprecipitated from the indicated cell lines, followed by 
immunoblotting with anti-ZO-2 (upper panel) and anti-pY (lower panel). B. Whole cell 
lysates from Csk-/- cells expressing Csk and those transformed by c-SrcYF were 
immunoblotted with anti-pY (lanes 1 and 2). Immunoprecipitates with anti-Csk (lanes 3 and 
4) and anti-ZO-2 (lanes 5 and 6) were immunoblotted with anti-pY. An arrow indicates the 
location of ZO-2.
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Figure 9. Interaction of ZO-2 with Csk SH2 domain
A. HEK293T cells were transfected with the indicated combinations of the expression 
vectors, and the whole cell lysates were immunoblotted with anti-pY and anti-Csk. KD: a 
kinase-deficient mutant, YF: a constitutively active c-SrcYF, W: wild-type, 2M: an SH2 
mutant, 3M: an SH3 mutant. B. ZO-2-myc (upper panels) and Csk (lower panels) were 
immunoprecipitated, and the complexes were immunoblotted with anti-pY, anti-myc, and 
anti-Csk.
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Figure 10. Csk binding regions in ZO-2
A schematic representation of ZO-2 structure and the deletion mutants (a–g) of ZO-2 used 
in this study. Locations of tyrosine residues are indicated on the full length ZO-2 (Y). The 
amino acid numbers at N- and C-terminus are shown. PDZ, PSD-95/Dlg/ZO-1; NLS, 
nuclear localization signal; GuK, guanylate kinase; PR, proline-rich domain.
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Figure 11. Csk binding regions in ZO-2
HEK293T cells were transfected with the indicated combinations of the expression vectors, 
and the whole cell lysates were immunoblotted with anti-FLAG and anti-HA (left panels). 
The lysates were then subjected to immunoprecipitation with anti-FLAG, and the 
precipitates were immunoblotted with anti-FLAG, anti-pY and anti-HA (right panels). The 
locations of immunoglobulin (Ig) are shown.
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Figure 12. Roles of Dok-1 and ZO-1/2 in the regulation of SFKs by Csk
Dok-1 plays roles as a site specific Csk adaptor downstream of growth factor receptor. 
ZO-1/2 is a site specific Csk anchor acting at the undercoat of cell-cell junctions. 
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PROTEIN ACESSION IDENTIFIED MASS MASCOT SEQUENCE
NAME NUMBER PEPTIDE ERROR SCORE COVERAGE
SEQUENCE (ppm)
14-3-3 protein zeta/delta gi|1526539 NLLSVAYK 95 29 8%
DICNDVLSLLEK 9 12
Caveolin-1 gi|6680854 HLNDDVVK 32 3 10%
SFLIEIQCISR 13 31
Cbp / PAG gi|81868799 IPPENAVDEILTAR 46 55 3%
Heat shock 70 kDa protein 5 gi|31981722 VMEHFIK 855 4 15%
TFAPEEISAMVLTK 46 30
ITPSYVAFTPEGER 54 45
TKPYIQVDIGGGQTK 44 27
NQLTSNPENTVFDAK 44 34
SQIFSTASDNQPTVTIK 78 21
IEIESFFEGEDFSETLTR 86 46
Heat shock 70 kDa protein 8 gi|51702275 MVNHFIAEFK 22 48 23%
FEELNADLFR 13 61
SQIHDIVLVGGSTR 26 52
TTPSYVAFTDTER 13 46
SFYPEEVSSMVLTK 27 31
NQVAMNPTNTVFDAK 15 70
IINEPTAAAIAYGLDK 60 73
TVTNAVVTVPAYFNDSQR 28 38
SINPDEAVAYGAAVQAAILSGDK 37 58
GPAVGIDLGTTYSCVGVFQHGK 11 48
paxillin gi|81902126 ELDELMASLSDFK 25 78 2%
Tensin-1 (Predicted) gi|94363487 LFGFVAR 62 21 19%
LLSGFGVDR 29 41
GDMTHELVR 145 40
HFLIETGPR 16 23
KGDMTHELVR 133 42
YWYKPEISR 11 24
SHPGGGPTVPSPGR 14 55
YSMPDNSPETR 91 14
VSSPPPTITQQGK 32 48
ERQPAEPPGPLR 22 26
TVGTNTPPSPGFGR 27 47
TPFQPMLDSSIR 17 44
VSAQGITLTDNQR 58 50
DSSGPANSTTDLLK 30 82
HAAYGGYSTPEDR 12 83
LVIPSRDPTDESK 11 29
YVHYFSGLLSGSIK 23 39
IIAVSFPSTANEENFR 43 66
Supplement Table 1. Analysis of Csk binding proteins by tandem mass spectrometry
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TPEEEPLNLEGLVAHR 39 68
VLEFGWPDLHTPALEK 29 48
SQSFPDVEPQLPQAPTR 100 24
FPDYGKVEFVFSYGPEK 122 7
ATSETLAADPTPAATIVHFK 58 31
HGGNYLLFNLSEQRPDITK 18 39
SKPSPQLSAETPVAALPEFPR 36 35
SQSVPGAWPGASPLSSQPLLGSSR 38 31
SPVQCVSPELALTIALNPGGRPK 42 51
Tensin-3 gi|134152676 DDRFPDYGK 20 16 7%
VSAQGITLTDNQR 22 57
HVVPAQVHVNGDAALK 50 0
YPPFSPPEPQLSSPASLHK 38 30
IIAVSFPASCSEESYLHSLQEVTR 63 17
LLIPERDPLEEIAENSPQTAANSAAELLK41 60
Tight junction protein 1, gi|15489342 GEEVTILAQK 222 2 1%
ZO-1 EEAVLFLLDLPK 17 55
Tight junction protein 2, gi|25059002 LQLVVLR 55 25 15%
ZO-2 LGHWLAVR 64 36
HALLDVTPK 62 37
YQEEGPVPQPR 75 28
MQELQEAQNAR 58 52
EDAVLYLLEIPK 89 61
SSEPVQHEENIR 57 22
STGDITAAGVTEASR 54 3
LATELPDLFQTAK 46 35
SNLPATAGSEIPGGSTK 63 49
INGTVTENMSLTDAR 58 54
RPVVLFGPIADIAMER 46 45
VFLRPSPEDEAIYGPNTK 55 22
VVMVNGTPMEDVLHSFAVQQLR 47 47
 71000000000000
Supplementary figure S1. Identification of novel Csk binding proteins, 
ZO-2
(A) A representative MS/MS spectrum assigned to ZO-2 are shown. (B) Amino acid 
sequence of mouse ZO-2. Matched peptides shown in Red.
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EDAVLYLLEIPK(701.93,2+) = mouse ZO2 (a.a.549-560)
K P IE L L Y L V A D
A
      1 MEEVIWEQYT VTLQKDSKRG FGIAVSGGRD NPHFENGETS IVISDVLPGG
     51 PADGLLQEND RVVMVNGTPM EDVLHSFAVQ QLRKSGKIAA IVVKRPRKVQ
    101 VAPLQGSPPL SHDDRGFEVI EEFDGRSFRS GYSERSRHSS HDMLSHSWEG
    151 NRERGRPHQR TQSRERERSR GRSLERGLDQ EDYGRSRERS RGRSLERGLD
    201 RDFVSRDHSR GRSIDRDYDR DYERSYHEAY EPDYGGGYSP SYDRRAHPET
    251 RYERSRSREH LRSRSPSPES RSRHEHKGQH DPDRPIGVLL TKSKANEEYG
    301 LRLGSQIFIK EMTRTGLATK DGNLHEGDII LKINGTVTEN MSLTDARKLI
    351 EKSRGKLQLV VLRDSKQTLI NIPALNDSDS EVEDISEIES NRSFSPEERR
    401 QQYSDQDYHS STEKLKERPS SREETSGRLS RMGATPTPFK STGDITAAGV
    451 TEASREPRYQ EEGPVPQPRT APRVFLRPSP EDEAIYGPNT KMVRFKKGDS
    501 VGLRLAGGND VGIFVAGIQE GTSAEQEGLQ EGDQILKVNT QDFRGLVRED
    551 AVLYLLEIPK GETVTILAQS RADVYRDILA CGRGDSFFIR SHFECEKETP
    601 QSLAFTRGEV FRVVDTLYDG KLGHWLAVRI GNELEKGLIP NKSRAEQMAS
    651 VQNAQRENAG DRADFWRMRG QRSSGGVKKN LRKSREDLAA AVSVSTKFPA
    701 YEKVLLREAG FKRPVVLFGP IADIAMERLA TELPDLFQTA KTEPKDAGSE
    751 KSSGVVRLNT VRQIIEQDKH ALLDVTPKAV DLLNYTQWFP IVIFFNPDSR
    801 QGVKTIRQRL SPTSNKSSRK LFDQANKLKK TCSHLFTATI NVNSANDGWF
    851 GSLKDSIQQQ QNEAVWVSEG KMEGMDDDAE DRMSYLTAMG ADYLSCDSRL
    901 ISDFEDTDGE GGAYTDNELE EPAEEPLVSS ITRSSEPVQH EENIRKSSPE
    951 PRAQMRRAAS RDQLRDASPP PAFKPEPPKA RSQNREDSFD YSKSNLPATA
   1001 GSEIPGGSTK GYPPPIAAKP AFGRPILKPS TPVPMPESEE VGESTEEQED
   1051 APRSVLGRVK IFEKMDHKAK LQRMQELQEA QNARIEIAQK HPDIYAVPIK
   1101 APKPDAGLPP HMSSRPPEPQ KAPSRLYQDT RGSYGSDPEE EEYRQQLAAH
   1151 SKRGYYSQPS RYRDTEL
B
Sapplementary figure S2. MS/MS spectra of Single-peptide-based protein 
identification.
MS/MS spectura and amino acid sequence of ZO-1 (A), 14-3-3 ζ/δ (B), Caveolin-1 (C), 
Cbp/PAG (D) and paxillin (E). Each spectrum shows the predicted peptide sequence and 
the identified fragment.
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EEAVLFLLDLPK(693.89,2+) = mouse ZO1 (a.a.481-492)
K P LD L L L V A EEF
A
74
SFLIEIQCISR(683.36,2+) = mouse Caveolin-1 (a.a.136-146)
R I E I F  SS  I  C Q
B
L
C
NLLSVAYK(454.76,2+) = mouse 14-3-3 protein zeta/delta (a.a.42-49)
K A V S LNLY
75
IPPENAVDEILTAR(769.41,2+) = mouse Cbp/PAG (a.a.138-151)
R ATL E D V A N E P PII
D
ELDELMASLSDFK(749.34,2+) = mouse Paxillin (a.a.265-277)
K F D L S M L E LEDS A
E
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